Incidence and Possible Causes of Prescribing Potentially Hazardous/Contraindicated Drug Combinations in General Practice
- 278 Downloads
Background: Preventing the use of medications where there is the potential for serious drug-drug interactions or drug-disease interactions (contraindications) is essential to ensure patient safety. Previous studies have looked at the incidence of prescribing contraindicated drug combinations, but little is known about the underlying reasons for the co-prescribing events. The objectives of this study were to estimate the incidence of prescribing contraindicated drug combinations in general practice and to explore the clinical context, possible causes and potential systems failures leading to their occurrence.
Methods: A list of contraindicated drug combinations was compiled according to established references. A search of computerised patient medication records was performed, followed by detailed chart review and assessment. The patient records from four general practices in an area of England were searched for a period of 1 year (1 June 1999–31 May 2000) to identify contraindicated drug combinations. All patients registered with the four participating practices during the study period were included (estimated n = 37 940). Medical records of the cases identified by the computer search were reviewed in detail and relevant information was extracted. Each case was then independently assessed by a pharmacist and a physician who judged whether the co-prescribing was justified and whether it was associated with an adverse drug event. Proximal causes and potential systems failures were suggested for each co-prescribing event.
Main outcome measures and results: Fourteen patients with potential drug-drug interactions and 50 patients with potential drug-disease interactions were identified. Overall, these represent an incidence of 1.9 per 1000 patient-years (95% CI 1.5, 2.3) or 4.3 per 1000 patients being concurrently prescribed ≥2 drugs per year (95% CI 3.2, 5.4). 62 cases involving 63 co-prescribing events were reviewed. Two-thirds of these events involved medications that were initiated by hospital doctors. Awareness of the potential drug-drug or drug-disease interactions was documented in one-third of the events at the time of initial co-prescribing. Within the study period, the co-prescribing was judged to be not justified in 44 events (70%). Potential drug-drug interactions possibly resulted in two adverse drug events. The majority of contraindicated co-prescribing related to drug-disease interactions involved the use of propranolol or timolol eye drops for patients receiving bronchodilators and the use of amiodarone for patients receiving levothyroxine sodium.
Conclusion: The prescribing of contraindicated drug combinations was relatively rare in this study. Multiple possible causes and systems failures were identified and could be used to develop strategies for the prevention of prescribing errors involving contraindicated drug combinations in primary care.
KeywordsAmiodarone Sumatriptan Drug Combination Adverse Drug Event Community Pharmacist
This study was funded by National Health Services R & D Support Funding for Primary Care, United Kingdom. We are grateful to the general practitioners and staff in the participating practices for their co-operation. At the time of manuscript revision, Yen-Fu Chen is affiliated with the Department of Public Health and Epidemiology, University of Birmingham and Michael Dewey with the Institute of Psychiatry, King’s College London, UK. The authors have no conflicts of interest that are directly relevant to the content of this study.
- 3.Sipilä J, Klaukka T, Martikainen J, et al. Occurrence of potentially harmful drug combinations among Finnish primary care patients. Int Pharm J 1995; 9: 104–7Google Scholar
- 9.Valuck RJ, Perlman JI, Anderson C, et al. Co-prescribing of medications used to treat obstructive lung disease, congestive heart failure and depression among users of topical beta blockers: estimates from three US Veterans Affairs Medical Centers. Pharmacoepidemiol Drug Saf 2001; 10: 511–6PubMedCrossRefGoogle Scholar
- 11.Hartshorn EA. Significance and interpretation of drug interaction information. Drug Intell Clin Pharm 1970; 4: 173Google Scholar
- 12.Stockley IH. Drug interactions. 5th ed. London: Pharmaceutical Press, 1999Google Scholar
- 13.Hansten PD, Horn JR. Hansten and Horn’s managing clinically important drug interactions. Vancouver (WA): Applied Therapeutics Inc, 1998Google Scholar
- 16.Joint Formulary Committee. British National Formulary 39. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2000Google Scholar
- 17.Newman CM, Price A, Davies DW, et al. Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy. Heart 1998; 79: 121–7Google Scholar
- 33.Coleman A, Ricketts L, Teal S, et al. An audit of hospital discharge and outpatient information from a primary care perspective. J Soc Adm Pharm 2001; 18: 226–31Google Scholar
- 37.Hazlet TK, Lee TA, Hansten PD, et al. Performance of community pharmacy drug interaction software. J Am Pharm Assoc 2001; 41: 200–4Google Scholar